Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire

• Published in: AIDS (London) Vol. 17; pp. S49 - S54
• Main Authors: ADJE-TOURE, Christiane A, CHEINGSONG, Rachanee, NOLAN, Monica, CHORBA, Terence, HENEINE, Walid, NKENGASONG, John N, GARCIA-LERMA, J. Gerardo, EHOLIE, Serge, BORGET, Marie-Yolande, BOUCHEZ, Jean-Marc, OTTEN, Ron A, MAURICE, Chantal, SASSAN-MOROKRO, Madeleine, EKPINI, René E
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 01.07.2003
• Subjects: Adult; AIDS/HIV; Anti-HIV Agents - therapeutic use; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiretroviral Therapy, Highly Active; Antiviral agents; Biological and medical sciences; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral - genetics; Female; Follow-Up Studies; HIV Infections - drug therapy; HIV Infections - immunology; HIV Infections - virology; HIV-2 - drug effects; HIV-2 - genetics; Human viral diseases; Humans; Indinavir - therapeutic use; Infectious diseases; Male; Medical sciences; Middle Aged; Mutation; Nelfinavir - therapeutic use; Patient Compliance; Pharmacology. Drug treatments; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Viral Load; Africa; Ivory Coast; HIV-2; Genotypic mutations; Blood plasma; Microbiological investigation; Nelfinavir; viral load response; Antiviral; Viral load; Human; Immunopathology; Treatment resistance; Enzyme; Retroviridae; Enzyme inhibitor; Genotype; AIDS; nelfinavir-based highly active antiretroviral therapy; Immune deficiency; Lentivirus; HIV-2 virus; phenotypic resistance; Infection; Virus; Numeration; Peptidases; Chemotherapy; Phenotype; Treatment; Viral disease; Hydrolases; Human immunodeficiency virus; Mutation; Protease inhibitor; indivavir-based highly active antiretroviral therapy
• ISSN: 0269-9370; 1473-5571
• DOI: 10.1097/00002030-200317003-00007

To describe changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of HIV-2-infected patients receiving antiretroviral (ARV) therapy in Abidjan, Côte d'Ivoire. Consecutive blood samples were collected from 18 HIV-2-infected ARV-naive patients who had received ARV therapy in the UNAIDS drug access initiative (UNAIDS-DAI) in Abidjan between August 1998 and July 2000. Changes in HIV-2 plasma viral load, CD4+ cell counts, and genotypic and phenotypic drug resistance testing were determined. At baseline, 11 (61%) of the 18 patients initiated highly active antiretroviral therapy (HAART) and seven (39%) received dual therapy. No significant change in median viral load was observed at 2 months (P = 0.09), at 6 months (P = 0.06), and at 12 months of therapy (P = 0.26). No significant increase in CD4+ cell counts was observed at 12 months (P = 0.10). All four patients on indinavir-containing HAART had undetectable viral loads at 2-4 months of therapy. However, none of seven patients on nelfinavir-containing HAART had a substantial decrease in viral load. Viruses from 14 patients were analyzed, 12 of which (86%) had at least one primary resistance mutation that is known to confer resistance to HIV-1 virus. Three patients had the multi-drug-resistant mutation, Q151M, two of whom showed reduced susceptibility to zidovudine, didanosine, stavudine and zalcitabine. Our limited findings show that nelfinavir-containing regimens may have limited virologic benefit to HIV-2-infected patients.